title: Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.
abstract: In a double-blind, placebo-controlled, randomized crossover study, 15 stable mild hyperglycemic patients without treatment and with features of metabolic syndrome were treated with cerivastatin (0.4 mg/day) or placebo for 3 months. The insulin sensitivity index during the euglycemic-hyperinsulinemic clamp (EHC; 5.4 mmol/l; 80 mU x m(-2) x min(-1)) was increased by cerivastatin treatment (66.39 +/- 3.9 nmol x lean body mass [LBM](-1) x min(-1) x pmol(-1) x l(-1)) as compared with placebo (58.37 +/- 3.69 nmol x LBM(-1) x min(-1) x pmol(-1) x l(- 1); P < 0.01) by 13.7%. Glucose oxidation during EHC was significantly higher with statin treatment (16.1 +/- 1.37 micromol x LBM(-1) x min(-1)) as compared with placebo (14.58 +/- 1.48 micromol x LBM(-1) x min(-1); P < 0.05). During hyperinsulinemia (approximately 800 pmol/l) in EHC steady-state, lipid oxidation was significantly decreased and respiratory quotient was significantly increased with statin treatment (0.33 +/- 0.05 mg x LBM(-1) x min(- 1), 0.94 +/- 0.01) as compared with placebo (0.48 +/- 0.06 mg x LBM(-1) x min(-1), 0.91 +/- 0.01; P < 0.01 and P < 0.05, respectively). During statin treatment, the first-phase insulin response increased from 2.07 +/- 0.28 to 2.82 +/- 0.38 pmol x l(-1) x pmol(-1) (P < 0.05). The second phase of insulin responses examined by C-peptide and insulin levels averaged during the hyperglycemic clamp (20 mmol/l) was unchanged. In conclusion, this study demonstrates that 0.4 mg cerivastatin therapy improves first-phase insulin secretion and increases insulin-mediated glucose uptake and respiratory quotient in the early state of obese type 2 diabetes.
authors.affiliation: Lipid and Atherosclerosis Unit, University Hospital Reina Sofía, Cordoba, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Paniagua
authors.forename: J
authors.initials: J
authors.lastname: López-Miranda
authors.forename: A
authors.initials: A
authors.lastname: Escribano
authors.forename: F J
authors.initials: FJ
authors.lastname: Berral
authors.forename: C
authors.initials: C
authors.lastname: Marín
authors.forename: D
authors.initials: D
authors.lastname: Bravo
authors.forename: E
authors.initials: E
authors.lastname: Paz-Rojas
authors.forename: P
authors.initials: P
authors.lastname: Gómez
authors.forename: M
authors.initials: M
authors.lastname: Barcos
authors.forename: J A
authors.initials: JA
authors.lastname: Moreno
authors.forename: F
authors.initials: F
authors.lastname: Pérez-Jiménez
mesh_terms: D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D019270:Fructosamine / Q000097:blood; D015309:Glucose Clamp Technique; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006946:Hyperinsulinism; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009765:Obesity; D010919:Placebos; D011725:Pyridines / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D019270:Fructosamine; D006442:Glycated Hemoglobin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007328:Insulin; D010919:Placebos; D011725:Pyridines; C086276:cerivastatin